Immunitybio Stock Analysis

Immunitybio Stock Analysis Notes

About 63.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.61. Immunitybio had not issued any dividends in recent years. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. To learn more about Immunitybio call Richard Adcock at 844 696 5235 or check out https://immunitybio.com.

Immunitybio Investment Alerts

Immunitybio Upcoming and Recent Events

Immunitybio Largest EPS Surprises

View All Earnings Estimates

Immunitybio Environmental, Social, and Governance (ESG) Scores

Immunitybio Stock Institutional Investors

Note, although Immunitybio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunitybio Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.4 B.

Immunitybio Profitablity

Management Efficiency

Immunitybio has return on total asset (ROA) of (0.4848) % which means that it has lost $0.4848 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.89 in 2025, whereas Return On Tangible Assets are likely to drop (1.18) in 2025. At this time, Immunitybio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 25.4 M in 2025, whereas Total Assets are likely to drop slightly above 299.1 M in 2025.

Technical Drivers

As of the 21st of March, Immunitybio retains the Risk Adjusted Performance of 0.0068, insignificant market risk adjusted performance, and Standard Deviation of 6.34. Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Immunitybio Price Movement Analysis

Immunitybio Insider Trading Activities

Immunitybio Outstanding Bonds

Immunitybio Predictive Daily Indicators

Immunitybio Corporate Filings

Immunitybio Forecast Models

Immunitybio's time-series forecasting models are one of many Immunitybio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunitybio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunitybio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunitybio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunitybio. By using and applying Immunitybio Stock analysis, traders can create a robust methodology for identifying Immunitybio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunitybio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunitybio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Immunitybio stock analysis indicators help investors evaluate how Immunitybio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunitybio shares will generate the highest return on investment. By understating and applying Immunitybio stock analysis, traders can identify Immunitybio position entry and exit signals to maximize returns.

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.